Status:
TERMINATED
Busulfan in Multiple Myeloma
Lead Sponsor:
Guido Tricot
Collaborating Sponsors:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Two main objectives of the study are: Primary: To determine the MTD of Busulfex ® that can be given safely over the least number of days to myeloma patients who are either ≥65 years of age (Group 1)...
Detailed Description
This study is for first line treatment for multiple myeloma patients in patients \>65 years or have renal insufficiency Busulfan introduces cytopenia much slower than melphalan while the time to recov...
Eligibility Criteria
Inclusion
- Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.
- Subjects must have symptomatic multiple myeloma at their new patient consult at HCI that, in the opinion of the enrolling physician, requires treatment.
- Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency, defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than 30mL/minute.
- Subjects must not have a history of chronic obstructive or chronic restrictive pulmonary disease. Subjects must demonstrate adequate pulmonary function studies defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity (DLCO).
- Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).
- Subjects must demonstrate adequate liver functions with total bilirubin and transaminase levels no higher than 1.5 times the institutional upper limit of normal. (If total bilirubin is \> 1.5 times the upper limit of normal, a direct bilirubin needs to be assessed. Subject eligible as long as the direct bilirubin is not \> 1.5 times the upper limit of normal)
- Subjects must have at least one evaluable myeloma marker by which to judge response: serum M protein \>1g/dL, free light chains in the serum that more than four times the upper limit of normal, urine M protein of ≥ 500 mg, urine free light chains of ≥ 500 mg/day, bone marrow plasmacytosis with \>20% plasma cells, extramedullary plasmacytosis, or MRI/FDG-PET/CT scan demonstrating 1 or more focal lesions due to myeloma.
- Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone pain.
- Subjects must be informed of the investigational nature of the study and must sign an IRB-approved informed consent in accordance with institutional and federal guidelines.
- Female participants of child-bearing potential must have a negative pregnancy test documented within 10 days of enrollment.
Exclusion
- Subjects must not have serum transaminases \>1.5 times the upper limit of normal and/or a direct bilirubin \>1.5 time the institutional upper limit of normal (direct bilirubin to be assessed only if the total bilirubin is \> 1.5 times the upper limit of normal)
- Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C infection. If serology antibody studies are positive, a quantitative PCR must be done to confirm.
- Subjects must not have a prior malignancy in which life expectancy, which in the opinion of the investigator, is more likely to be determined by the prior malignancy than the myeloma. Patients must not be currently receiving therapy for the prior malignancy.
- Subjects must not have had a prior autologous or allogeneic bone marrow transplant.
- Subjects must not be pregnant or nursing. Women and men of reproductive potential may not participate unless they agree to use an effective contraceptive method.
- Patients who have \< 3 million CD34 cells/kg stored for this protocol.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00934232
Start Date
August 1 2009
End Date
February 1 2012
Last Update
May 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.